ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,320.76
0.43%
Dow Jones
42,313.00
0.33%
Gold vs US Dollar
2,658.34
0.00%
Brent Oil
72.01
0.00%
Bitcoin
65,680.35
-0.30%
Pepperstone
Advertisement
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. TransCode Therapeutics Inc (RNAZ) Share Price

RNAZ TransCode Therapeutics Inc

0.6399
0.0247 (4.01%)
28 Sep 2024 - Closed
Delayed by 15 minutes
 Name  Symbol  Market  Type  ISIN  Description 
 TransCode Therapeutics Inc NASDAQ:RNAZ NASDAQ Common Stock  
     Change  % Chg  Cur  Bid  Offer  High  Low  Open  Volume  Chg Time
Upgrade Icon
 		 RN  NRN 
   0.0247 4.01 0.6399 0.4545 0.685 0.6985 0.505 0.606 2,671,402 04:00:07   
 Sector  Turnover  Profit  EPS - Basic  PE ratio  Mkt Cap 
 Pharmaceutical Preparations  -18.55M -1.0742 -0.59 10.62M
 Type  Size  Price  Time  Units 
 20 200 0.6399 23:59:35 USD
 
Pre-Market and After-Hours
Recent News
DateTimeSource
HeadlineMore RNAZ News
27/09/202421:02EDGAR2Form 8-K - Current report
17/09/202412:00GLOBETransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate
10/09/202412:00GLOBETransCode Therapeutics Announces Publication of Study with Lead Therapeutic Candidate Revealing Mechanisms Behind Candidate’s Preclinical Efficacy Against Metastatic Cancer
05/09/202412:00GLOBETransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate
28/08/202411:02EDGAR2Form 8-K - Current report
16/08/202422:04EDGAR2Form 8-K - Current report
15/08/202412:00GLOBETransCode Therapeutics Announces Phase 1 Clinical Trial Initiation
Period
Draw mode
Data Downloads for RNAZ

Export historical price information open, high, low, close, volume (OHLCV) to Excel

Intraday price data (2 weeks, 1 minute bars)


Loading Follow Feed...

Latest TransCode Therapeutics Inc Articles